Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 医師 は 患者 に 体重 を 落とす 動機 を 与え ます

医師 は 患者 に 体重 を 落とす 動機 を 与え ます

Anita Slomski

    JAMA
    |December 28, 2016

    関連する実験動画

    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    1.4K
    Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
    03:05

    Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

    Published on: November 21, 2025

    693
    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    1.7K
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    1.4K
    Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
    03:05

    Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

    Published on: November 21, 2025

    693
    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    1.7K

    関連する概念動画

    Drug Dosing: Obese Patients01:21

    Drug Dosing: Obese Patients

    321
    In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
    321
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    336
    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    336
    Obesity01:24

    Obesity

    1.5K
    The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
    1.5K
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    259
    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    259
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    541
    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    541
    Stress Prevention and Stress Management Techniques VI01:30

    Stress Prevention and Stress Management Techniques VI

    303
    Adopting a healthier lifestyle often requires overcoming significant challenges, but leveraging psychological, social, and cultural resources can facilitate meaningful change. Effective self-change hinges on understanding and applying key tools such as motivation and goal setting, which help sustain efforts toward long-term health benefits.
    Motivation and Self-Determination
    Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
    303
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー